Couldn't agree more.
The company is not trading on its fundamentals, or its world wide opportunity.
With no profit yet, and no dividend, it's a short seller's delight.
Just don't get in the way when all the elephants try to exit the door at the same time!
I mentioned a possible buyout, but like Groucho Marx, "I'm against it".
November, with the as yet unannounced conference call, plus the Investor Day conference on Nov 17 should give some clarity as to the true direction this company is headed.
I will give the board a full report of Investor Day. I have already registered to be there.
imo nvdq is severely undervalued. Its billion(s) world wide opportunity, its monopoly and moat of patients, its several years of head start against future competitors, and its astute, experienced management are not yet factored into its current pps. All that's missing is profit. That spark in a dry forest, together with the ridiculous short interest will sooner or later result in the meltup of the share price---oh did I mention a buyout at a very fine premium?
I attended Investor Day both years. I don't keep such records, but it seems to me that I knew about the Nov 18, 2013 date many weeks prior, almost certainly more than a month ahead of time.
Looks like the managements of nvdq and isrg share the same philosophy: put the building blocks into place, and let the markets eventually price it in. They certainly are not day traders!
There's a rather ignorant (imo) sell piece on Novadaq that can be accessed via Google. The anonymous author recommends selling the shares because the stock has dropped and analysts have lowered their estimates. Time to buy!!
To me the most significant part of this announcement is that firefly will ship with ALL Xi systems. Apparently the value of firefly is such that it is no longer an optional feature. This is very exciting for both companies, but particularly for Novadaq....hence the pop in nvdaq shares today, and maybe yesterday. as well.
According to Barron's: even though the stock was down today on huge volume, the fact remains that there were more trades on the buy side than the sell side, and furthermore the volume of the trades on the upside was more than the volume of the trades on the downside ( "uptick/downtick ratio" was 1.07).
Based on this, I believe that a bottom may have been put in today.....time will tell. Comments?
Thanks Endo for all the info! Outstanding work! I'm surprised that the company would open up with individual investors such as yourself. Tremendous!!! Looks like the company is a screaming buy.
I think you're asking the right questions...unless Dave Martin's exit is material,( which I don't think it is).
Certainly never thought that the pps could be sliced in half.
The guidance about (only) 35% growth in the 3Q didn't help,but unless something else is afoot, that's not a worry. Today's news on Yahoo Finance references Taglich's renewing its buy rating but also lowering the TP from 19 to 16, based on "reduced minimum valuations" (that's read as LIfecell not pulling their weight).
But since Lifecell will be thrown overboard (IMO) the stand alone company's earnings will be immediately accretive. In the meantime we have to be patient.
Breaking off from LIfecell should be immediately accretive to earnings. Their world wide opportunity is also unfolding nicely. The rollout of the nuclear medicine application in 2015 can't hurt either.
Patience is a virtue.
" Asian sales in Japan and China - through partners - have not even begun yet (regulatory approvals coming)."
I'm not aware yet of any guidance or specifics regarding SPY sales/prospects in Japan or mainland China....can you fill me in with any references?
With the current pps of ~15...
and we compound at 40% (growth) going out 5 years, we come up with a pps of 80.
Now that's a buyout price I could live with!
Thanks for your post.
Small correction: " Recently, Intuitive won a negligence case by a jury vote of 10 to 2. That verdict will impact on other pending cases". Actually this was old news from 2013, spun by Bloomberg as fresh news to keep their negative narrative going. Let's hope the best is yet to come.
It's a classic, time honored strategy honed by Apple, Microsoft and a host of other companies. That is, lower investor expectations and set up a "beat" to boost the share price. Certainly no CEO is going to repeatedly mention 40% growth,and then fall short. jmo